Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salvage Chemoradiation for Recurrent Esophageal Cancer
NCT03731442Phase 3Recruiting
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Nov 2018
- Primary completion
- Oct 2022
- Countries
- 1
01
Overview
Phase 3, open-label trial (2 arms), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Overall Survival at 3 years. Started Nov 2018; status: recruiting.
Beyond the preview
Go deeper on NCT03731442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03731442.